Filter Results

Clinical Studies

Open

Contact Us for the Latest Status

  • A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study With An Open-label Period And Long-term Extension To Assess The Efficacy And Safety Of Rilzabrutinib In Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) (LUMINA 3) Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approximately 90 male and female participants ≥ 18 years of age with a confirmed diagnosis of primary wAIHA.

    Following a 4-week screening period, eligible participants will be randomized in a 2:1 ratio to receive rilzabrutinib or placebo in primary analysis period (PAP) for a duration of up to 24 weeks. All participants who completed PAP will then continue in open-label period (OLP) to receive rilzabrutinib for a duration of 28 weeks. Upon the completion of OLP, only participants who demonstrate Hb increase during the last 8 weeks of OLP per specified criteria in the protocol will be eligible to continue in long-term extension (LTE) of the study. The duration of the LTE period will be from the first-participant-in (FPI)-LTE until the last participant completes 52 weeks in LTE. The safety follow-up period of this study following treatment completion or discontinuation will be 2 weeks.

Closed for Enrollment

.